Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

IIROC Trading Halt - RVX

Canada NewsWire July 25, 2017

CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.

Newsfile July 25, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile July 25, 2017

Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

PR Newswire July 10, 2017

Resverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial

PR Newswire Asia July 10, 2017

Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Canada NewsWire June 28, 2017

Resverlogix Comments on TSX Trader Notes

Canada NewsWire June 21, 2017

IIROC Trade Resumption - Resverlogix Corp.

Newsfile June 20, 2017

Resverlogix Closes $10 Million of Equity Subscriptions

Canada NewsWire June 20, 2017

IIROC Trade Halt - Resverlogix Corp.

Newsfile June 20, 2017

Resverlogix to Raise Up To $10 Million

Canada NewsWire June 9, 2017

Resverlogix Announces Overnight Marketed Equity Offering

Canada NewsWire June 8, 2017

Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

Canada NewsWire June 5, 2017

Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain

Canada NewsWire May 31, 2017

Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Canada NewsWire May 30, 2017

Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

PR Newswire May 23, 2017

Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

Canada NewsWire May 15, 2017

Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

Canada NewsWire March 17, 2017

Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

Canada NewsWire March 15, 2017

Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Canada NewsWire February 23, 2017